Tenofovir alafenamide hemifumarate
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319909

CAS#: 1392275-56-7 (hemifumarate)

Description: Tenofovir alafenamide hemifumarate, also known as Tenofovir alafenamide fumarate (2:1), is a nucleotide reverse transcriptase inhibitor (NRTIs) and a novel prodrug of tenofovir. By blocking reverse transcriptase, TAF prevent HIV from multiplying and can reduce the amount of HIV in the body. Tenofovir alafenamide is a prodrug, which means that it is an inactive drug. In the body, tenofovir alafenamide is converted to tenofovir diphosphate (TFV-DP). Tenofovir alafenamide fumarate was approved in November 2015 for treatment of HIV-1.


Price and Availability

Size
Price

100mg
USD 150
1g
USD 650
10g
USD 2950
Size
Price

200mg
USD 250
2g
USD 950
20g
USD 3850
Size
Price

500mg
USD 450
5g
USD 1850
50g
USD 4750

Tenofovir alafenamide hemifumarate, purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 20g may be 2 weeks.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 319909
Name: Tenofovir alafenamide hemifumarate
CAS#: 1392275-56-7 (hemifumarate)
Chemical Formula: C46H62N12O14P2
Exact Mass:
Molecular Weight: 1069.0195
Elemental Analysis: C, 51.68; H, 5.85; N, 15.72; O, 20.95; P, 5.79


Related CAS #: 379270-38-9 (fumarate)   1392275-56-7 (hemifumarate)   379270-37-8 (free base)  

Synonym: TAF; GS734; GS-734; GS 734; GS 7340; GS-7340; GS7340; Tenofovir alafenamide hemifumarate; Tenofovir alafenamide fumarate (2:1).

IUPAC/Chemical Name: isopropyl ((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)-L-alaninate hemifumarate

InChi Key: SVUJNSGGPUCLQZ-FQQAACOVSA-N

InChi Code: InChI=1S/2C21H29N6O5P.C4H4O4/c2*1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27;5-3(6)1-2-4(7)8/h2*5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24);1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*15-,16+,33+;/m11./s1

SMILES Code: O=C(O)/C=C/C(O)=O.C[C@H](N[P@@](OC1=CC=CC=C1)(CO[C@H](C)CN2C=NC3=C(N)N=CN=C23)=O)C(OC(C)C)=O.C[C@H](N[P@@](OC4=CC=CC=C4)(CO[C@H](C)CN5C=NC6=C(N)N=CN=C56)=O)C(OC(C)C)=O


Technical Data

Appearance:
White to off-white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

Related CAS#
CAS#379270-38-9 =Tenofovir alafenamide fumarate, 1:1
CAS#1392275-56-7= Tenofovir alafenamide hemifumarate, 2:1
CAS#379270-37-8 = Tenofovir alafenamide free base


References

1: Majewska A, Mlynarczyk-Bonikowska B, Malejczyk M, Mlynarczyk G, Majewski S. Antiviral Medication in Sexually Transmitted Diseases. Part II: HIV. Mini Rev Med Chem. 2015;15(2):93-103. PubMed PMID: 25751258.

2: Sax PE, Zolopa A, Brar I, Elion R, Ortiz R, Post F, Wang H, Callebaut C, Martin H, Fordyce MW, McCallister S. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):52-8. doi: 10.1097/QAI.0000000000000225. PubMed PMID: 24872136.

3: Markowitz M, Zolopa A, Squires K, Ruane P, Coakley D, Kearney B, Zhong L, Wulfsohn M, Miller MD, Lee WA. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother. 2014 May;69(5):1362-9. doi: 10.1093/jac/dkt532. Epub 2014 Feb 6. PubMed PMID: 24508897.

4: Flexner C, Saag M. The antiretroviral drug pipeline: prospects and implications for future treatment research. Curr Opin HIV AIDS. 2013 Nov;8(6):572-8. doi: 10.1097/COH.0000000000000011. Review. PubMed PMID: 24100879.

5: De Clercq E. Dancing with chemical formulae of antivirals: a personal account. Biochem Pharmacol. 2013 Sep 15;86(6):711-25. doi: 10.1016/j.bcp.2013.07.012. Epub 2013 Jul 19. Review. PubMed PMID: 23876344.

6: Ruane PJ, DeJesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, Zhong L, Ramanathan S, Rhee MS, Fordyce MW, Yale K. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):449-55. doi: 10.1097/QAI.0b013e3182965d45. PubMed PMID: 23807155.

7: De Clercq E. A Cutting-Edge View on the Current State of Antiviral Drug Development. Med Res Rev. 2013 Mar 11. doi: 10.1002/med.21281. [Epub ahead of print] PubMed PMID: 23495004.

8: Saag MS. New and investigational antiretroviral drugs for HIV infection: mechanisms of action and early research findings. Top Antivir Med. 2012 Dec;20(5):162-7. Review. PubMed PMID: 23363694.

9: Permpalung N, Putcharoen O, Avihingsanon A, Ruxrungtham K. Treatment of HIV infection with once-daily regimens. Expert Opin Pharmacother. 2012 Nov;13(16):2301-17. doi: 10.1517/14656566.2012.729040. Epub 2012 Oct 8. Review. PubMed PMID: 23043453.

10: Lepist EI, Phan TK, Roy A, Tong L, Maclennan K, Murray B, Ray AS. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother. 2012 Oct;56(10):5409-13. doi: 10.1128/AAC.01089-12. Epub 2012 Jul 30. PubMed PMID: 22850510; PubMed Central PMCID: PMC3457391.

11: Llibre JM, Clotet B. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. AIDS Rev. 2012 Jul-Sep;14(3):168-78. Review. PubMed PMID: 22833060.

12: Kersh EN, Luo W, Zheng Q, Adams DR, Hanson D, Youngpairoj AS, Cong ME, Butler K, Hendry RM, McNicholl JM, Heneine W, Garcia-Lerma JG. Reduced inflammation and CD4 loss in acute SHIV infection during oral pre-exposure prophylaxis. J Infect Dis. 2012 Sep 1;206(5):770-9. doi: 10.1093/infdis/jis422. Epub 2012 Jun 27. PubMed PMID: 22740713; PubMed Central PMCID: PMC3491742.

13: Babusis D, Phan TK, Lee WA, Watkins WJ, Ray AS. Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. Mol Pharm. 2013 Feb 4;10(2):459-66. doi: 10.1021/mp3002045. Epub 2012 Jul 12. PubMed PMID: 22738467.

14: Birkus G, Kutty N, He GX, Mulato A, Lee W, McDermott M, Cihlar T. Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol Pharmacol. 2008 Jul;74(1):92-100. doi: 10.1124/mol.108.045526. Epub 2008 Apr 22. PubMed PMID: 18430788.

15: Birkus G, Wang R, Liu X, Kutty N, MacArthur H, Cihlar T, Gibbs C, Swaminathan S, Lee W, McDermott M. Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrob Agents Chemother. 2007 Feb;51(2):543-50. Epub 2006 Dec 4. PubMed PMID: 17145787; PubMed Central PMCID: PMC1797775.

16: Cihlar T. Nucleotide HIV reverse transcriptase inhibitors: tenofovir and beyond. Curr Opin HIV AIDS. 2006 Sep;1(5):373-9. doi: 10.1097/01.COH.0000239849.20828.09. PubMed PMID: 19372836.

17: Van Rompay KK, Kearney BP, Sexton JJ, Colón R, Lawson JR, Blackwood EJ, Lee WA, Bischofberger N, Marthas ML. Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus. J Acquir Immune Defic Syndr. 2006 Sep;43(1):6-14. PubMed PMID: 16810108.

18: Lee WA, He GX, Eisenberg E, Cihlar T, Swaminathan S, Mulato A, Cundy KC. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005 May;49(5):1898-906. PubMed PMID: 15855512; PubMed Central PMCID: PMC1087627.

19: Chapman H, Kernan M, Prisbe E, Rohloff J, Sparacino M, Terhorst T, Yu R. Practical synthesis, separation, and stereochemical assignment of the PMPA pro-drug GS-7340. Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):621-8. PubMed PMID: 11563079.

20: Eisenberg EJ, He GX, Lee WA. Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood. Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):1091-8. PubMed PMID: 11562963.